Navigation Links
Reminder: Exelixis Announces December 5 Webcast of Its Third Annual R&D Day
Date:11/28/2007

SOUTH SAN FRANCISCO, Calif., Nov. 28 /PRNewswire-FirstCall/ -- Exelixis, Inc. (Nasdaq: EXEL) announced today that it will hold its Third Annual R&D Day on Wednesday, December 5, 2007 from 10:00 a.m. ET / 7:00 a.m. PT to 2:00 p.m. ET / 11:00 a.m. PT in New York. The company will discuss updates to its development pipeline, its collaborations, including those with GSK, BMS and Genentech, and its financial outlook for 2007.

Speakers:

-- George Scangos, PhD, President & Chief Executive Officer of Exelixis,

Inc.

-- Michael Morrissey, PhD, President of Research & Development of

Exelixis, Inc.

-- Frank Karbe, Executive Vice President & Chief Financial Officer of

Exelixis, Inc.

-- Peter Lamb, PhD, Senior Vice President, Discovery Research & Chief

Scientific Officer of Exelixis, Inc.

-- Gisela Schwab, MD, Senior Vice President and Chief Medical Officer of

Exelixis, Inc.

-- Steven Sherman, MD of MD Anderson Cancer Center

-- Vince Miller, MD of Memorial Sloan-Kettering Cancer Center

The event will be webcast and may be accessed in the Event Calendar page under Investors at http://www.exelixis.com.

An archive of this webcast will be available until 9:00 p.m. PT/12:00 a.m. ET on January 4, 2008. Access numbers for this replay are: 1-888-286-8010 (domestic) and 1-617-801-6888 (international); the replay passcode number is: 21270665.

About Exelixis

Exelixis, Inc. is a development-stage biotechnology company dedicated to the discovery and development of novel small molecule therapeutics for the treatment of cancer and other serious diseases. The company is leveraging its fully integrated drug discovery platform to fuel the growth of its development pipeline, which is primarily focused on cancer. Currently, Exelixis' broad product pipeline includes investigational compounds in phase 2 and phase 1 clinical development for cancer and renal disease. Exelixis has established strategic corporate alliances with major pharmaceutical and biotechnology companies, including GlaxoSmithKline, Bristol-Myers Squibb Company, Genentech, Wyeth Pharmaceuticals and Daiichi-Sankyo. For more information, please visit the company's web site at http://www.exelixis.com.


'/>"/>
SOURCE Exelixis, Inc.
Copyright©2007 PR Newswire.
All rights reserved

Related biology technology :

1. Reminder: XTL to Hold a Conference Call Today at 8:30 am EDT to Discuss the Phase IIb Clinical Trial of Bicifadine for the Treatment of Diabetic Neuropathic Pain
2. Dow AgroSciences and Exelixis Plant Sciences Announce Major Research Collaboration, Asset Purchase to Advance Gene Discovery and Validation
3. Exelixis Reports Encouraging Interim Data From a Phase 2 Trial of XL647 as First-Line Therapy for Non-Small Cell Lung Cancer
4. Exelixis Announces Closing of Public Offering of Common Stock
5. Exelixis Submits XL880 Diligence Report to GlaxoSmithKline
6. Exelixis Announces November 5 Webcast of its 2007 Third Quarter Financial Results Conference Call
7. Exelixis Announces Third Quarter 2007 Financial Results and Business Update
8. Exelixis Sells 80% Stake in Artemis to Taconic
9. Exelixis Announces December 5 Webcast of Its Third Annual R&D Day
10. Exelixis Announces November 27 Webcast of Presentation at the 19th Annual Piper Jaffray Health Care Conference
11. Exelixis Announces November 28 Webcast of Presentation at the Lazard Capital Markets Fourth Annual Healthcare Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/29/2016)... , ... April 29, 2016 , ... Intelligent Implant Systems ... the FDA via 510(k) for sale in the United States. These components expand ... thoraco-lumbar fusions. With one-level sales beginning in October of 2015, the company has ...
(Date:4/28/2016)... Hill, Conn. (PRWEB) , ... April 28, 2016 ... ... of financing and ongoing support for Connecticut's innovative, growing companies, today announced the ... digital health and financial technology (fintech) companies. , “VentureClash looks to ...
(Date:4/27/2016)... ... , ... Cambridge Semantics, the leading provider of Smart Data analytic ... been named to The Silicon Review’s “20 Fastest Growing Big Data Companies of 2016.” ... the needs of end users facing some of the most complex data challenges in ...
(Date:4/27/2016)... British Columbia , April 27, 2016 /PRNewswire/ ... oder "NanoStruck") (CSE: NSK) (OTCPink: NSKQB) ( ... im Anschluss an ihre Pressemitteilung vom 13. August ... erhalten hat, ihre Finanzen um zusätzliche 200.000.000 Einheiten ... 4.000.000 Kanadische Dollar zu bringen. Davon wurden 157.900.000 ...
Breaking Biology Technology:
(Date:3/14/2016)... http://www.apimages.com ) - ... - Renvoi : image disponible via AP Images ( ... --> DERMALOG, le leader de l,innovation ... d,empreintes digitales pour l,enregistrement des réfugiés en Allemagne. ... produire des cartes d,identité aux réfugiés. DERMALOG dévoilera ...
(Date:3/10/2016)...   Unisys Corporation (NYSE: UIS ) today ... is testing its biometric identity solution at the Otay Mesa ... help identify certain non-U.S. citizens leaving the country. ... help determine the efficiency and accuracy of using biometric technologies ... run until May 2016. --> the United ...
(Date:3/8/2016)... 2016   Valencell , the leading innovator ... has secured $11M in Series D financing. The ... venture fund being launched by UAE-based financial services ... investors TDF Ventures and WSJ Joshua Fund. Valencell ... triple-digit growth and accelerate its pioneering innovation in ...
Breaking Biology News(10 mins):